Medicare beneficiaries who rely on semaglutide for diabetes or weight management are set to pay sharply less starting January 1, 2027, when negotiated maximum fair prices take effect for 15 drugs covering cancer and chronic conditions. The Centers for Medicare and Medicaid Services set the new monthly cost of semaglutide at about $274, a reduction that will reshape how many seniors budget for one of the most widely prescribed medications in the country. Both Ozempic and Wegovy are among the drugs receiving lower Medicare pricing under the second cycle of the agency’s drug price negotiation program.
How the $274 semaglutide price changes Part D economics
The negotiated price lands at a fraction of what many Medicare Part D enrollees currently face at the pharmacy counter. Once the maximum fair price, or MFP, kicks in at the start of 2027, Part D plans will have a strong financial incentive to place semaglutide on preferred formulary tiers because the plan’s own cost exposure drops with the lower negotiated rate. That shift could reduce prior-authorization barriers for semaglutide faster than for competing GLP-1 drugs that were not selected for negotiation, since plans typically loosen access controls on drugs that cost them less.
Whether that formulary shift actually translates into fewer denied claims within the first six months of 2027 depends on how quickly insurers update their coverage criteria. Plans often finalize formulary designs months before a new benefit year, so the MFP announcement gives them a runway to adjust. Non-negotiated GLP-1 alternatives, by contrast, would remain at higher list prices, making them less attractive to plan sponsors trying to control spending. The practical result for a beneficiary choosing between two clinically similar drugs could be a faster approval process for semaglutide and a slower one for its competitors.
Lower negotiated prices also interact with the broader Part D redesign phases created under the Inflation Reduction Act. With a $274 monthly price, many beneficiaries using semaglutide will reach the catastrophic threshold more slowly than they would at current list prices, which can reduce the share of the year in which they face higher coinsurance. At the same time, plans and the federal government will shoulder a different mix of costs as spending shifts from high list prices with large rebates to lower, more transparent negotiated prices. How plans respond with premiums and benefit structures for 2027 will depend partly on how many high-cost users they expect to move onto semaglutide at the new MFP.
CMS negotiation mechanics and the IPAY 2027 cycle
The price reduction stems from the second round of negotiations authorized by the Inflation Reduction Act. HHS published final guidance for the IPAY 2027 cycle, which required manufacturers to submit detailed data on research costs, patent holdings, and production expenses before CMS issued offers and counteroffers. Semaglutide was included in this cycle, and the resulting MFP applies to both its diabetes and obesity indications sold under the Ozempic and Wegovy brand names.
CMS released a broader savings announcement for 15 major drugs alongside links to its official MFP explanation files. The agency framed the reductions as direct relief for seniors facing high out-of-pocket costs on drugs they use daily, emphasizing that the negotiated prices are intended to reflect clinical benefit and real-world utilization as well as manufacturer-submitted data. The Government Accountability Office separately reviewed the program’s early rollout in a report titled “Inflation Reduction Act of 2022: Initial Implementation of Medicare Drug Pricing Provisions,” cataloged as GAO-25-106996, which examined the negotiation process structure and the consequences manufacturers face for declining to participate.
The CMS index of selected drugs and negotiated prices serves as the authoritative file distribution point for machine-readable MFP data, including CSV and XLSX formats. That repository will be the place to verify the exact per-unit pricing once CMS posts the final effectuation files that Part D plans must use to calculate beneficiary cost-sharing. Plan actuaries, pharmacy benefit managers, and independent researchers will rely on those files to model how the $274 semaglutide price flows through to premiums, deductibles, and tiered copays.
What the public record still does not show
Several pieces of the pricing puzzle have not been disclosed. The manufacturer-submitted data on research and development spending, patent portfolios, and production costs that CMS used to calculate its initial offer for semaglutide remain confidential. Without those inputs, independent analysts cannot reconstruct how CMS arrived at the $274 figure or assess whether the negotiated price reflects a steep discount or a modest trim from the agency’s internal ceiling. The negotiation statute also restricts CMS from releasing certain proprietary information, limiting outside scrutiny of the assumptions behind the final MFP.
Novo Nordisk, which manufactures both Ozempic and Wegovy, has not released public statements detailing how it plans to comply with the MFP or whether it will adjust supply chains, rebate structures, or commercial pricing in response. That silence leaves open the question of whether the negotiated Medicare price will put downward pressure on what private insurers pay, or whether the company will maintain a two-tier pricing structure that preserves higher prices in the commercial market. It also remains unclear whether the company will alter patient assistance programs or copay coupons that currently help some non-Medicare patients afford semaglutide.
Beneficiary-level impact data tied specifically to the new MFPs has not appeared on Medicare.gov or Medicaid.gov beyond general navigation resources. Until CMS publishes plan-specific formulary filings for the 2027 benefit year, enrollees will not know their exact copay or coinsurance for semaglutide under the negotiated rate. Those filings typically arrive in the fall before a new plan year begins, which means seniors shopping during the 2026 open enrollment period should look for updated plan formularies that reflect the MFP. Advocates have urged CMS and plans to present this information in clearer language so beneficiaries can distinguish between list prices, negotiated prices, and their own out-of-pocket obligations.
What beneficiaries should do before 2027 coverage begins
Anyone currently enrolled in a Part D plan that covers Ozempic or Wegovy should start by confirming how the drug is treated on their 2024 and 2025 formularies, including the tier, any prior authorization requirements, and step-therapy rules. While those details will not automatically carry over to 2027, understanding today’s baseline makes it easier to recognize meaningful changes once the MFP takes effect. Beneficiaries can request a coverage determination or exception if they face restrictive utilization management, although plans retain discretion within Medicare rules.
In 2026, as plans prepare their 2027 benefit designs, beneficiaries and caregivers should pay close attention to the Annual Notice of Change documents that arrive each fall. Those materials must describe any shifts in premiums, deductibles, and formulary status, including whether semaglutide moves to a more favorable tier. Because the $274 MFP lowers the underlying cost to plans, many enrollees may see reduced coinsurance or flat copays for semaglutide relative to 2024 or 2025 levels, but that will vary by plan and region.
During the 2026 open enrollment period, seniors who use or expect to use semaglutide should compare plans not only on premium but also on how they cover GLP-1 drugs overall. A plan that heavily favors semaglutide at the negotiated price may be attractive for someone already stable on Ozempic or Wegovy, while another plan might still offer better terms for alternative therapies. Comparing pharmacy networks and mail-order options can also matter, since negotiated prices apply at the point of sale, but dispensing fees and network arrangements affect the final out-of-pocket cost.
Beneficiaries with limited incomes should explore whether they qualify for the Low-Income Subsidy, also known as Extra Help, which can further reduce out-of-pocket costs for Part D drugs, including those subject to MFPs. Although the negotiated price for semaglutide will lower spending even for those who do not qualify for subsidies, Extra Help can make the difference between a manageable monthly bill and a cost that still strains a fixed income. State Health Insurance Assistance Programs and local aging agencies can help seniors navigate these options well before the 2027 changes take effect.
Finally, patients should stay in close contact with their prescribers as 2027 approaches. Clinicians will need to understand evolving formularies to avoid unnecessary treatment interruptions or surprise denials when plans shift utilization management in response to the new semaglutide price. By combining careful plan selection, early review of 2027 benefit materials, and proactive conversations with providers, Medicare beneficiaries stand the best chance of translating the $274 maximum fair price into real, predictable savings at the pharmacy counter.
Free tool for readers: Most people don’t find out they’re off track until it’s too late. You can see where your retirement stands with a free Retirement Safety Score in about five minutes — no sign-up required to see it.
